Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00476463
Other study ID # HIV-NAT 023
Secondary ID
Status Completed
Phase Phase 2
First received May 20, 2007
Last updated February 18, 2016
Start date April 2005
Est. completion date December 2008

Study information

Verified date February 2016
Source The HIV Netherlands Australia Thailand Research Collaboration
Contact n/a
Is FDA regulated No
Health authority Thailand: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Combination therapy with anti-HBV activity may both increase HBV suppression rates and reduce emergence of resistant strains. Several new therapeutic agents are currently in development, however combination therapy trials in the HBV-infected population have only recently commenced. No such trials have been undertaken in the HIV/HBV co-infected population.


Description:

The primary study objective is to compare HBV DNA suppression to levels below the limit of detection (<400 copies/ml) by week 48 in each treatment group. Virological and clinical anti-HBV efficacy of tenofovir and emtricitabine in antiretroviral naive patients with HIV/HBV co-infection.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date December 2008
Est. primary completion date December 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Written informed consent

- Documented HIV infection (positive serology for HIV-1 and detectable HIV-1 RNA)

- Age 18 - 70 years

- HBV DNA > 106 copies/ml

- HBsAg positive for > 6 months

In case documented duration of HBsAg seropositive is less than 6 months (this situation is most likely to occur in patients newly presenting to the HIV-outpatient clinic) the patient is eligible if the patient is:

1. HBsAg positive and

2. HBc core IgM antibody negative and

3. the liver biopsy gives evidence for a chronic active hepatitis. Thus making it likely that this patient has acquired the HBV infection more than 6 months ago.

- ALT < 10 x ULN

- Creatinine <= 2.0mg/dl

- Platelet count >= 50,000/mm3

- HIV-1 therapy naive

- No prior exposure to anti-HBV agents (LAM, adefovir, TDF) although prior IFN treatment allowed

Exclusion Criteria:

- HCV-RNA positive or Anti-HAV IgM positive

- Acute hepatitis (serum ALT > 1000 U/L)

- Prior LAM, TDF, or ADV therapy

- Active opportunistic infection

- Other causes of chronic liver disease identified ( autoimmune hepatitis, haemochromatosis, Wilsons disease, alfa-1-antitrypsin deficiency)

- Concurrent malignancy requiring cytotoxic chemotherapy

- Decompensated or Child's C cirrhosis

- Alfa-fetoprotein (AFP) > 3X ULN (unless negative CT scan or MRI within 3 months of entry date)

- Pregnancy or lactation

- Any other condition which in the opinion of the investigator might interfere with compliance or outcome of the study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Emtricitabine
Emtricitabine 200 mg OD + Zidovudine 300 mg BID + EFV OD compared to TDF + FTC + EFV

Locations

Country Name City State
Thailand HIV-NAT Thai Red Cross AIDS Research Center Bangkok

Sponsors (3)

Lead Sponsor Collaborator
The HIV Netherlands Australia Thailand Research Collaboration Gilead Sciences, Ministry of Health, Thailand

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary HBV DNA suppression to levels below the limit of detection (<400 copies/ml) week 48 Yes
Secondary HBV suppression as measured by comparison of AUC measurements at 12 and 24 weeks 12 and 24 weeks Yes
Secondary Proportion of patients with undetectable HBV DNA in serum at 12 and 24 weeks 12 and 24 weeks Yes
Secondary Rate of HBeAg and HBsAg seroconversion at 12, 24 and 48 weeks. 12, 24 and 48 weeks Yes
Secondary Rate of emergence of LAM-resistant HBV genotypes at 48 weeks. 48 weeks Yes
Secondary Rate of hepatic cytolysis (ALT level > 5x ULN). 48 weeks Yes
Secondary Change from baseline in ALT levels and time to ALT normalization. 48 weeks Yes
Secondary Suppression of plasma HIV-RNA (< 50 copies/ml) through 48 weeks. 48 weeks Yes
Secondary Changes in CD4+ /CD8+ cell counts through 48 weeks 48 weeks Yes
Secondary Toxicity 48 weeks Yes
Secondary Assessment of effect of therapy on histological changes in the liver and effect on ccc-HBV-DNA 48 weeks No
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2